.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FB01_InotuzumabOzogamicin.InotuzumabOzogamicin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FB01_InotuzumabOzogamicin.InotuzumabOzogamicin| name: | InotuzumabOzogamicin | |
| ATC code: | L01FB01 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1.8 | mg |
| volume of distribution: | 12.3 | L |
| clearance: | 0.0333 | L/h/kg |
| other parameters in model implementation | ||
Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody-drug conjugate used in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is approved for medical use and works by delivering a cytotoxic agent directly to cancerous B-cells expressing CD22.
Pharmacokinetic parameters were reported from clinical studies in adult patients with relapsed or refractory B-cell precursor ALL following intravenous administration.